Sequential chemotherapy and radiotherapy as sandwich therapy for the treatment of high risk endometrial cancer.
- Author:
Lisa N ABAID
1
;
Mark A RETTENMAIER
;
John V BROWN
;
John P MICHA
;
Alberto A MENDIVIL
;
Marie A WABE
;
Bram H GOLDSTEIN
Author Information
- Publication Type:Original Article
- Keywords: Chemotherapy; Endometrial cancer; Gynecologic oncology; Radiotherapy
- MeSH: Anemia; Carboplatin; Disease-Free Survival; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Incidence; Neutropenia; Paclitaxel; Retrospective Studies; Thrombocytopenia
- From:Journal of Gynecologic Oncology 2012;23(1):22-27
- CountryRepublic of Korea
- Language:English
- Abstract: OBJECTIVE: The purpose of this retrospective study was to assess the tolerability and efficacy of sequential chemotherapy and radiotherapy for the treatment of high risk endometrial cancer. METHODS: We conducted a retrospective study of previously untreated high risk endometrial cancer patients who received sequential chemotherapy and radiotherapy in accordance with the sandwich approach from June 2008 until June 2011. High risk endometrial cancer patients underwent complete surgical staging followed by adjuvant therapy encompassing sequential chemotherapy, radiation therapy and consolidation chemotherapy. RESULTS: The study analysis comprised 32 endometrial cancer patients. All subjects were treated with carboplatin and paclitaxel chemotherapy; currently, 186 cycles have been administered and 94% of patients have completed the planned number of cycles. Grade 3 neutropenia developed in 1 (3.1%) patient; there was no incidence of grade 4 neutropenia. Moreover, we observed grade 3 anemia in four (12.5%) patients and grade 4 anemia in one (3.1%) patient. One (3.1%) patient developed grade 3 thrombocytopenia; grade 4 thrombocytopenia was not observed. Five patients exhibited progressive disease, three of whom have since expired; mean progression free survival and follow-up were 17.4 months and 18.9 months, respectively. CONCLUSION: The preliminary results from our study suggest that the sandwich approach to treating high risk endometrial cancer patients is feasible. Hematologic toxicity was well tolerated and non-hematologic toxicity was mild and easily managed. Further study of this novel regimen in a larger patient population with extended follow-up is necessary.
